Sharemaestro company report · Combined company view · NASDAQ

Aurinia Pharmaceuticals Inc

AUPH · Broad strength across the profile

1 of 3 available weekly market readings are positive.

Latest completed factor comparison: 18 Sep 2026. Chart evidence is dated separately; price updates do not recalculate this factor edition.

The selected research question · Combined company view

How broad is the support behind the combined score?

Look across value, business strength and price strength, then use growth and capital return to find weak spots that the combined score can conceal.

Breadth behind the score

Broad strength across the profile

4 of 5 measured pillars have a standing of at least 65. Growth and capital return add context; they are not equal-weight components of the combined score.

Latest change: 3 improving, 1 weakening and 1 unchanged across the 5 comparable focus pillars since the previous edition.

4/5 strong
Focus pillars with standing ≥65. This is a breadth check, not a new combined score.
Value
68/100

-12.0 points vs screen median

Strong in 62% of 16 observed editions
Business strength
97/100

+27.0 points vs screen median

Strong in 100% of 16 observed editions
Price strength
84/100

+20.0 points vs screen median

Strong in 100% of 16 observed editions
Growth
95/100

+35.0 points vs screen median

Strong in 100% of 16 observed editions
Capital return
29/100

-40.0 points vs screen median

Strong in 56% of 16 observed editions

The comparison uses companies qualifying for this screen in the same universe and edition. Medians require at least five companies. Historical strength counts actual factor observations; it does not claim historical screen membership.

01 · The company in perspective

The shape of the evidence

Higher means stronger relative standing.
Value68/100
+22.0 points vs Healthcare median
Business strength97/100
+51.0 points vs Healthcare median
Price strength84/100
+31.0 points vs Healthcare median
Growth95/100
+44.0 points vs Healthcare median
Capital return29/100
-15.5 points vs Healthcare median

Vertical marks show the peer median · 940 company records in the comparison.

Current research reading

Value finding support

Value and business strength are joined by stronger price standing.

Check whether weekly trend and participation support the price ranking.

Strongest pillar

Business strength

97/100 standing

Weakest pillar

Capital return

29/100 standing

The strongest and weakest pillars describe this profile, not changes in company performance. The history below shows whether the readings are improving.

Beneath the factor profile

How well does the business support the score?

Derived from the saved company inputs · 18 Sep 2026
Cash value78/100
Cash backing66/100
Business durability65/100
Financial resilience100/100
Capital discipline41/100
Price support67/100

These established Sharemaestro cash-research scores summarise cash backing, durability, resilience and capital discipline. Higher is stronger on the available tests. They are separate from universe ranks and are not percentiles or probabilities. Missing components remain unavailable.

02 · Market confirmation

Is the price supporting the case?

Full chart terminal ↗
Trend SignalPositivelatest completed chart observation
Market DynamicsNot positivelatest completed chart observation
Relative StrengthNot positivelatest completed chart observation
Price / Fair Value+61.2%positive is above the reference

03 · What is changing

A strong reading matters more when it lasts.

7 Jun 2026 – 18 Sep 2026
Factor standing, one edition at a time

Read across for persistence. Read down for breadth. Each cell is an actual published observation.

80–9965–7940–640–39No reading
Company factor history. Higher scores mean stronger standing in the comparison universe.
Factor7 Jun202614 Jun202621 Jun202628 Jun20265 Jul202612 Jul202619 Jul202626 Jul20262 Aug20269 Aug202616 Aug202623 Aug202630 Aug20264 Sep202611 Sep202618 Sep2026LatestChange
CombinedFocus920.0points
ValueFocus68-6.0points
Business strengthFocus97+1.0points
Price strengthFocus84+8.0points
GrowthFocus950.0points
Capital returnFocus29+1.0points

Hover or focus a cell to inspect its dated reading. Arrow keys move between factors and editions. Scroll across for more dates.

Changes since the previous edition
Price strength+8.0 pts76 → 84
Value-6.0 pts74 → 68
Business strength+1.0 pts96 → 97
Capital return+1.0 pts28 → 29
Growth0.0 pts95 → 95

Changes compare 11 Sep 2026 with 18 Sep 2026. The underlying company period did not change between these editions. Prices, peer rankings and other inputs can still move the scores. Changes in a relative score do not, by themselves, identify a cause.

04 · Competitive position

Company strength, in its peer context

Explore Healthcare ↗

Value and Business strength

AUPH is highlighted against companies in the Strong combined scores screen. Select a point to compare the same research angle. Up to 250 companies shown.

Has price kept pace?

Price returns to 18 Sep 2026. The comparison is the median of companies in the same sector with a reading, not a traded portfolio.

3 monthsAUPH+2.7%Sector median1.4%Difference+1.3 pp
6 monthsAUPH+20.5%Sector median5.3%Difference+15.2 pp
12 monthsAUPH+30.0%Sector median1.9%Difference+28.1 pp

Relative standing is the useful comparison.

A rising share price can still trail its peers. A company with falling prices can still outperform a weaker sector. Compare the return gap with the factor profile before drawing a conclusion.

At least five sector observations are required to display a median. Returns exclude dividends. These are completed historical returns, not forward estimates.

05 · Staying power and price risk

Separate company standing from the ride.

Strong factor evidence does not remove price risk.
Combined factor standing · strong editions100%score ≥65 in 16 observed editions
Annualised volatility31.3%stored one-year daily measure · factor date
Input coverage97%available factor inputs, not certainty

Drawdown measures the weekly close below its running high within the displayed price history. It starts at zero and is not an all-time drawdown. Persistence counts observed editions only; missing weeks are not filled in.

06 · Research playbook

What would strengthen — or weaken — this reading?

Conditions to monitor, not a trade instruction.
Build the Combined company view case

Several pillars strengthen together

Compare changes across all five perspectives; watch for new company inputs and loss of price support.

1 of 3 available weekly market readings are positive.

Challenge the case

The score depends on fewer strong pillars

Capital return is the weakest measured focus pillar at 29/100. Check whether it is recovering, stable or deteriorating in the history above.

A loss of screen qualification, lower coverage or deterioration across several readings would require a fresh review.

Compare the alternatives

Keep the research question consistent

Compare AUPH with other companies selected by Strong combined scores. A stronger overall score does not necessarily mean stronger evidence for this particular approach.

Open this screen →

Screen membership

Where AUPH qualifies

The same selection rules used by the Company Screener.

A traceable Sharemaestro report

Built from the record we have.

This report uses published Sharemaestro factor snapshots and stored completed weekly prices and indicators. Company inputs are translated into comparable standing, change and context. The page does not fetch live accounts or infer missing company results.

Scores use the established higher-is-stronger Sharemaestro display convention and are relative to US - USD. Sector medians compare those same universe scores; they do not re-rank the company. Peer medians exclude missing readings.

The company period is the period end used in the factor edition, not its filing date. Stored history is an observation record, not a claim of a point-in-time investable backtest. None of these scores is a probability or expected return.

Historical price series may reflect provider adjustments. The combined score is a summary, not a substitute for the distinct strengths, weaknesses and data coverage shown above.

Evidence context